Deze beweringen zijn uitstekend gedocumenteerd door de onderstaande onderzoeken.

GRB Skinner. Thyroxin should be tried in clinically hypothyroid but biochemecially eutyroid patients.
BMJ 1997; 314: 1764

H. Zulewski, B Muller, P. Exer e.a. Estimation of tissue hypothyroidism bu a new clinical score: evaluation of
patients with various grades of hypothyriodism and controls.
J Clin Endocrinol Matab 1997; 82/3:771-6

WD.Fraser, EM Biggart, D.St J.O'REilly e.a. Are biochemical tests of thyroid function of any value in monitoring
patients recieving thyroxine replacement?
BMJ 1986;293: 808-10

JA Franklin, EM Black, J Betteridge e.a. Comparison of second and third generation method for measurement of serum
thyropin in patients with overt hyperthyroidism, patients with receiving thyroxine therapy, and those with
nontrhyroidal illness.
J Clin Endocrinol Metab 1994; 78:1368-71

C Meier e.a. Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with overt
primary thyroid failure: cross sectional survey.
BMJ 2003;326:311-312.

Andersen S, Pedersen KM, Bruun NH, Laurberg P.
Narrow individual variations in serum T4 and T3 in normal subjects: a clue to the understanding of subclinical thyroid disease.
J Clin Endocrinol Metab 2002; 87: 1068-72.
Editorial: Colin M Dayan, Ponnusamy Saravanan, Graham Bayly. the Lancet volume 360, 9330 august 2002